602 related articles for article (PubMed ID: 29042174)
1. Results of Upfront Therapy for Marginal Zone Lymphoma.
Ortega JL; Cabanillas F; Rivera N; Tirado-Gomez M; Hallman D; Pardo WI; Bruno M
Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):879-883. PubMed ID: 29042174
[TBL] [Abstract][Full Text] [Related]
2. State-of-the-art therapeutics: marginal-zone lymphoma.
Bertoni F; Zucca E
J Clin Oncol; 2005 Sep; 23(26):6415-20. PubMed ID: 16155028
[TBL] [Abstract][Full Text] [Related]
3. High-dose therapy and autologous stem cell transplantation in marginal zone lymphomas: a retrospective study by the EBMT Lymphoma Working Party and FIL-GITMO.
Avivi I; Arcaini L; Ferretti VV; Boumendil A; Finel H; Milone G; Zaja F; Liliana D; Musso M; Didier B; Bachy E; Wattad M; Nicolas-Virelizier E; Gramatzki M; Bourhis JH; Caillot D; Haenel A; Held G; Thieblemont C; Jindra P; Pohlreich D; Guilhot F; Kroschinsky F; Wahlin B; Scheid C; Ifrah N; Berthou C; Dreger P; Montoto S; Conconi A
Br J Haematol; 2018 Sep; 182(6):807-815. PubMed ID: 29984825
[TBL] [Abstract][Full Text] [Related]
4. Bendamustine-rituximab regimen in untreated indolent marginal zone lymphoma: experience on 65 patients.
Morigi A; Argnani L; Lolli G; Broccoli A; Pellegrini C; Nanni L; Stefoni V; Coppola PE; Carella M; Casadei B; Sabattini E; Cavo M; Zinzani PL
Hematol Oncol; 2020 Oct; 38(4):487-492. PubMed ID: 32594531
[TBL] [Abstract][Full Text] [Related]
5. Primary cutaneous marginal zone B-cell lymphoma: response to treatment and disease-free survival in a series of 137 patients.
Servitje O; Muniesa C; Benavente Y; Monsálvez V; Garcia-Muret MP; Gallardo F; Domingo-Domenech E; Lucas A; Climent F; Rodriguez-Peralto JL; Ortiz-Romero PL; Sandoval J; Pujol RM; Estrach MT
J Am Acad Dermatol; 2013 Sep; 69(3):357-65. PubMed ID: 23796549
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of R-CVP followed by rituximab maintenance therapy for patients with advanced marginal zone lymphoma: consortium for improving survival of lymphoma (CISL) study.
Oh SY; Kim WS; Kim JS; Kim SJ; Yoon DH; Yang DH; Lee WS; Kim HJ; Yhim HY; Jeong SH; Won JH; Lee S; Kong JH; Lim SN; Ji JH; Kwon KA; Lee GW; Lee JH; Lee HS; Shin HJ; Suh C
Cancer Commun (Lond); 2019 Oct; 39(1):58. PubMed ID: 31619290
[TBL] [Abstract][Full Text] [Related]
7. Primary nodal marginal zone lymphomas of splenic and MALT type.
Campo E; Miquel R; Krenacs L; Sorbara L; Raffeld M; Jaffe ES
Am J Surg Pathol; 1999 Jan; 23(1):59-68. PubMed ID: 9888704
[TBL] [Abstract][Full Text] [Related]
8. Survival of patients with marginal zone lymphoma: analysis of the Surveillance, Epidemiology, and End Results database.
Olszewski AJ; Castillo JJ
Cancer; 2013 Feb; 119(3):629-38. PubMed ID: 22893605
[TBL] [Abstract][Full Text] [Related]
9. Stage IV marginal zone B-cell lymphoma--prognostic factors and the role of rituximab: Consortium for Improving Survival of Lymphoma (CISL) study.
Oh SY; Kim WS; Kim JS; Kim SJ; Lee S; Lee DH; Won JH; Hwang IG; Kim MK; Lee SI; Chae YS; Yang DH; Kang HJ; Choi CW; Park J; Kim HJ; Kwon JH; Lee HS; Lee GW; Eom HS; Kwak JY; Suh C; Kim HJ
Cancer Sci; 2010 Nov; 101(11):2443-7. PubMed ID: 20831770
[TBL] [Abstract][Full Text] [Related]
10. Activity of rituximab plus cyclophosphamide, doxorubicin/mitoxantrone, vincristine and prednisone in patients with relapsed MALT lymphoma.
Raderer M; Wohrer S; Streubel B; Drach J; Jager U; Turetschek K; Troch M; Puspok A; Zielinski CC; Chott A
Oncology; 2006; 70(6):411-7. PubMed ID: 17220639
[TBL] [Abstract][Full Text] [Related]
11. Primary radiation therapy in patients with localized orbital marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT Lymphoma).
Son SH; Choi BO; Kim GW; Yang SW; Hong YS; Choi IB; Kim YS
Int J Radiat Oncol Biol Phys; 2010 May; 77(1):86-91. PubMed ID: 19632068
[TBL] [Abstract][Full Text] [Related]
12. Treatment of gastric marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue with rituximab, cyclophosphamide, vincristine and prednisone.
Aguiar-Bujanda D; Llorca-Mártinez I; Rivero-Vera JC; Blanco-Sánchez MJ; Jiménez-Gallego P; Mori-De Santiago M; Limeres-Gonzalez MA; Cabrera-Marrero JC; Hernández-Sosa M; Galván-Ruíz S; Hernández-Sarmiento S; Saura Grau S; Bohn-Sarmiento U
Hematol Oncol; 2014 Sep; 32(3):139-44. PubMed ID: 24123108
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA/IELSG36 study.
Iannitto E; Bellei M; Amorim S; Ferreri AJM; Marcheselli L; Cesaretti M; Haioun C; Mancuso S; Bouabdallah K; Gressin R; Tripodo C; Traverse-Glehen A; Baseggio L; Zupo S; Stelitano C; Castagnari B; Patti C; Alvarez I; Liberati AM; Merli M; Gini G; Cabras MG; Dupuis J; Tessoulin B; Perrot A; Re F; Palombi F; Gulino A; Zucca E; Federico M; Thieblemont C
Br J Haematol; 2018 Dec; 183(5):755-765. PubMed ID: 30407629
[TBL] [Abstract][Full Text] [Related]
14. Splenic marginal zone lymphoma: Prognostic factors, role of watch and wait policy, and other therapeutic approaches in the rituximab era.
Perrone S; D'Elia GM; Annechini G; Ferretti A; Tosti ME; Foà R; Pulsoni A
Leuk Res; 2016 May; 44():53-60. PubMed ID: 27030961
[TBL] [Abstract][Full Text] [Related]
15. Treatment of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) with mitoxantrone, chlorambucil and prednisone (MCP).
Wöhrer S; Drach J; Hejna M; Scheithauer W; Dirisamer A; Püspök A; Chott A; Raderer M
Ann Oncol; 2003 Dec; 14(12):1758-61. PubMed ID: 14630681
[TBL] [Abstract][Full Text] [Related]
16. Combination therapy with rituximab and intravenous or oral fludarabine in the first-line, systemic treatment of patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type.
Salar A; Domingo-Domenech E; Estany C; Canales MA; Gallardo F; Servitje O; Fraile G; Montalbán C
Cancer; 2009 Nov; 115(22):5210-7. PubMed ID: 19672998
[TBL] [Abstract][Full Text] [Related]
17. Non-MALT marginal zone lymphoma.
Thieblemont C; Davi F; Noguera ME; Brière J
Curr Opin Hematol; 2011 Jul; 18(4):273-9. PubMed ID: 21577105
[TBL] [Abstract][Full Text] [Related]
18. Stage I and II MALT lymphoma: results of treatment with radiotherapy.
Tsang RW; Gospodarowicz MK; Pintilie M; Bezjak A; Wells W; Hodgson DC; Crump M
Int J Radiat Oncol Biol Phys; 2001 Aug; 50(5):1258-64. PubMed ID: 11483337
[TBL] [Abstract][Full Text] [Related]
19. Nodal marginal zone lymphoma: Clinical features, diagnosis, management and treatment.
Tadmor T; Polliack A
Best Pract Res Clin Haematol; 2017; 30(1-2):92-98. PubMed ID: 28288722
[TBL] [Abstract][Full Text] [Related]
20. Pulmonary marginal zone B-cell lymphoma of MALT type--what is a prognostic factor and which is the optimal treatment, operation, or chemotherapy?: Consortium for Improving Survival of Lymphoma (CISL) study.
Oh SY; Kim WS; Kim JS; Kim SJ; Kwon HC; Lee DH; Won JH; Hwang IG; Kim MK; Lee SI; Chae YS; Yang DH; Lee GW; Choi CW; Park J; Suh C; Kim HJ
Ann Hematol; 2010 Jun; 89(6):563-8. PubMed ID: 20024551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
